Clinical Trial Update: CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial of temsirolimus (CCI-779) in soft tissue sarcoma and gastrointestinal stromal tumor has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Soft Tissue Sarcoma

Drugs mentioned

• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED